Rauch Jennifer N, Valois Eric, Solley Sabrina C, Braig Friederike, Lach Ryan S, Audouard Morgane, Ponce-Rojas Jose Carlos, Costello Michael S, Baxter Naomi J, Kosik Kenneth S, Arias Carolina, Acosta-Alvear Diego, Wilson Maxwell Z
University of California, Santa Barbara, Department of Molecular, Cellular, and Developmental Biology, Santa Barbara, California, USA.
Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California, USA.
J Clin Microbiol. 2021 Mar 19;59(4). doi: 10.1128/JCM.02402-20.
The COVID-19 pandemic has created massive demand for widespread, distributed tools for detecting SARS-CoV-2 genetic material. The hurdles to scalable testing include reagent and instrument accessibility, availability of highly trained personnel, and large upfront investment. Here, we showcase an orthogonal pipeline we call CREST (Cas13-based, rugged, equitable, scalable testing) that addresses some of these hurdles. Specifically, CREST pairs commonplace and reliable biochemical methods (PCR) with low-cost instrumentation, without sacrificing detection sensitivity. By taking advantage of simple fluorescence visualizers, CREST allows a binary interpretation of results. CREST may provide a point-of-care solution to increase the distribution of COVID-19 surveillance.
J Clin Microbiol. 2021-3-19
Drug Discov Today. 2021-8
Genes (Basel). 2025-7-25
Biosensors (Basel). 2024-9-26
Methods Microbiol. 2022
Int J Mol Sci. 2023-8-30
NPJ Microgravity. 2023-6-21
Adv Sci (Weinh). 2023-8
3D Print Med. 2020-8-15
Nat Biotechnol. 2020-4-16
Nat Med. 2020-4-15
Lancet Infect Dis. 2020-3-30
Nature. 2020-4-1